R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's R&D?
- Summit Therapeutics (SMMT) reported R&D of $132.62M in Q1 2026.
- How has Summit Therapeutics's R&D changed year-over-year?
- Summit Therapeutics's R&D increased by 158.7% year-over-year, from $51.27M to $132.62M.
- What is the long-term trend for Summit Therapeutics's R&D?
- Over 4 years (2021 to 2025), Summit Therapeutics's R&D has grown at a 58.4% compound annual growth rate (CAGR), from $85.35M to $537.67M.
- What does R&D mean?
- The total amount spent on developing new products and technologies.
- How do you interpret R&D?
- An increase typically signals aggressive investment in future growth, while a decrease may indicate cost-cutting or a maturing pipeline.
- How does R&D compare across companies?
- High R&D intensity is standard for early-stage biotechs; peers often show R&D as a large percentage of total operating expenses.